ArticleEBioMedicine2016
Monoclonal antibodies against DNA-binding tips of DNABII proteins disrupt biofilms in vitro and induce bacterial clearance in vivo.
Article in EBioMedicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
71 citing papers in PubMed, 101 citations in OpenAlex.
- Monoclonal Antibodies Targeting Bacterial Infections: A Broad Review of the Field.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026Review
- The natural human adaptive IgG-specific immune response is skewed towards non-protective tail domains of DNABII proteins.Frontiers in immunology · 2026Article
- Rapid means of biofilm disruption induce the newly released (NRel) phenotype of enhanced antibiotic sensitivity.Frontiers in microbiology · 2026Article
- Stress-induced toxic genomic R-loops support biofilm extracellular matrix formation.Nature communications · 2025Article
- Stress-hardening behaviour of biofilm streamers.Nature communications · 2025Article
- Respiratory tract antimicrobial peptides more effectively killed multiple methicillin-resistantMicrobiology spectrum · 2025Article
- Review
- Targeting bacterial transcription factors for infection control: opportunities and challenges.Transcription · 2025Review
- An engineered peptide derived from the innate immune effector high-mobility group box 1 disrupts and prevents dual-genera biofilms formed by common respiratory tract pathogens.FEMS microbiology letters · 2025Article
- Straightforward MALDI-TOF MS based screening approach for selection of recombinant protein-expressingBiotechnology notes (Amsterdam, Netherlands) · 2025Article
- Human PMNs exhibit greater engulfment, NETosis, and enhanced migration when incubated with nontypeableFrontiers in microbiology · 2025Article
- Periprosthetic joint infections: state-of-the-art.Archives of orthopaedic and trauma surgery · 2024Review
- Article
- Multimodal evaluation of drug antibacterial activity reveals cinnamaldehyde analog anti-biofilm effects againstBiofilm · 2024Article
- Oral and middle ear delivery of otitis media standard of care antibiotics, but not biofilm-targeted antibodies, alter chinchilla nasopharyngeal and fecal microbiomes.NPJ biofilms and microbiomes · 2024Article
- Beyond the double helix: the multifaceted landscape of extracellular DNA inFrontiers in cellular and infection microbiology · 2024Review
- The overlooked bacterial pandemic.Seminars in immunopathology · 2024Review
- Disruption of nontuberculous mycobacteria biofilms induces a highly vulnerable to antibiotic killing phenotype.Biofilm · 2023Article
- Biofilm formation: mechanistic insights and therapeutic targets.Molecular biomedicine · 2023Review
- Review
11 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
The vast majority of chronic and recurrent bacterial diseases are attributed to the presence of a recalcitrant biofilm that contributes significantly to pathogenesis. As such, these diseases will require an innovative therapeutic approach. We targeted DNABII proteins, an integral component of extracellular DNA (eDNA) which is universally found as part of the pathogenic biofilm matrix to develop a biofilm disrupting therapeutic. We show that a cocktail of monoclonal antibodies directed against specific epitopes of a DNABII protein is highly effective to disrupt diverse biofilms in vitro as well as resolve experimental infection in vivo, in both a chinchilla and murine model. Combining this monoclonal antibody cocktail with a traditional antibiotic to kill bacteria newly released from the biofilm due to the action of the antibody cocktail was highly effective. Our results strongly support these monoclonal antibodies as attractive candidates for lead optimization as a therapeutic for resolution of bacterial biofilm diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.